Evidence map›Paper›PMID 36938892›Full record

Trial reportLeukemia & lymphoma2023

Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.

Ryan D Cassaday, Lucas C Zarling, Kelsey-Leigh A Garcia, Olga Sala-Torra, Philip A Stevenson, Christen H Martino, Yajuan J Liu, Min Fang, Mary-Elizabeth M Percival, Anna B Halpern and 10 more

Open access · greenAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia & lymphoma, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

Ryan D CassadayDepartment of Medicine, University of Washington, Seattle, WA, USA.ORCID 0000-0002-3424-2425
Lucas C ZarlingDepartment of Medicine, University of Washington, Seattle, WA, USA.
Kelsey-Leigh A GarciaDepartment of Medicine, University of Washington, Seattle, WA, USA.
Olga Sala-TorraClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Philip A StevensonClinical Statistics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Christen H MartinoDepartment of Medicine, University of Washington, Seattle, WA, USA.
Yajuan J LiuDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Min FangClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Mary-Elizabeth M PercivalDepartment of Medicine, University of Washington, Seattle, WA, USA.ORCID 0000-0002-7016-951X
Anna B HalpernDepartment of Medicine, University of Washington, Seattle, WA, USA.
Pamela S BeckerDepartment of Medicine, University of Washington, Seattle, WA, USA.
Vivian G OehlerDepartment of Medicine, University of Washington, Seattle, WA, USA.
Andrei R ShustovDepartment of Medicine, University of Washington, Seattle, WA, USA.
Jason P CooperDepartment of Medicine, University of Washington, Seattle, WA, USA.
Johnnie J OrozcoDepartment of Medicine, University of Washington, Seattle, WA, USA.
Paul C HendrieDepartment of Medicine, University of Washington, Seattle, WA, USA.
Roland B WalterDepartment of Medicine, University of Washington, Seattle, WA, USA.ORCID 0000-0002-9268-3341
Jerald P RadichDepartment of Medicine, University of Washington, Seattle, WA, USA.
Lorinda A SomaDepartment of Pathology, City of Hope National Medical Center, Duarte, CA, USA.
Elihu H EsteyDepartment of Medicine, University of Washington, Seattle, WA, USA.
University of Washington · USCity Of Hope National Medical Center · USFred Hutch Cancer Center · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
NCI NIH HHS P30 CA015704
6 · The paper itself

Abstract

Treatments for adults with newly-diagnosed acute lymphoblastic leukemia (ALL) may be prohibitively toxic and/or resource-intense. To address this, we performed a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH). Imatinib or dasatinib was added for Ph + disease; rituximab was added when CD20+. Fifty-three patients were evaluable: 28 with Ph + disease, and 25 with Ph-. All patients had ≥1 high-risk clinical feature. Measurable residual disease-negativity by multiparameter flow cytometry within 4 cycles was achieved in 71% in patients with Ph + ALL and 64% in Ph - ALL. Median overall survival (OS) was 49 months, with a 2-year OS of 71%. Median relapse-free survival (RFS) in the 47 patients that attained morphologic remission was 24 months, with a 2-year RFS of 57%. Early mortality was 2%. In summary, DA-EPOCH yields deep and durable remissions in adults with ALL comparable to some resource-intense strategies but with a low rate of treatment-related death.

Indexed as

DoxorubicinPrecursor Cell Lymphoblastic Leukemia-LymphomaAdultAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideEtoposideHumansPrednisoneRituximabVincristineCyclophosphamideDoxorubicinEtoposidePrednisoneRituximabVincristineAcute lymphoblastic leukemiaadultchemotherapyclinical trialmeasurable residual disease

Identifiers

PMID36938892
PMCPMC10357946
OpenAlexW4327893175

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.